Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel

Takuo Yamai1, Kenji Ikezawa1, Erika Hiraga1, Yasuharu Kawamoto1, Takeru Hirao1, Sena Higashi1, Kazuma Daiku1, Shingo Maeda1, Yutaro Abe1, Makiko Urabe1, Yugo Kai1, Ryoji Takada1, Tasuku Nakabori1, Nobuyasu Fukutake1, Hiroyuki Uehara1, Masashi Fujita2, Kazuyoshi Ohkawa1

1 Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan, 2 Department of Onco-Cardiology, Osaka International Cancer Institute, Osaka, Japan

*ikezawa-ke@oici.jp

Abstract

Background
Pancreatic cancer is associated with a high thromboembolism risk. We investigated the significance of early venous thromboembolism (VTE) detection in patients with unresectable metastatic pancreatic cancer (UR-MPC) who received first-line chemotherapy with gemcitabine plus nab-paclitaxel (GnP).

Methods
This single-center retrospective study enrolled 174 patients with UR-MPC who underwent GnP as a first-line chemotherapy from April 2017 to March 2020. The early detection of VTE (deep venous thrombosis and pulmonary thromboembolism) was defined as diagnosis by the first follow-up CT scan after the initiation of chemotherapy. We compared the patients with early detection of VTE (VTE (+) group) with the others (VTE (-) group). We examined overall survival (OS), progression free survival (PFS), severe adverse events, and predictors associated with OS using the Cox proportional hazards model.

Results
Early detection of VTE was observed in 17 patients (9.8%). Thirteen patients were diagnosed with VTE at treatment initiation, and four patients were diagnosed after treatment initiation. The median time to diagnosis after treatment initiation was 55 days (range: 31–71 days). Only 3 patients were symptomatic. The VTE (+) group exhibited worse OS and PFS than the VTE (-) group (OS: 259 days vs. 400 days, P < 0.001; PFS: 120 days vs. 162 days, P = 0.008). The frequency of grade 3–4 adverse events was not significantly different.
Although the performance status was poorer in the VTE (+) group, VTE was identified as a statistically significant independent predictor for OS in multivariate analyses (HR, 1.87; 95% CI, 1.02–3.44; P = 0.041).

**Conclusions**

Early VTE detection is a predictor of a poor prognosis in UR-MPC patients who receive GnP as first-line chemotherapy, suggesting that screening VTE for patients with UR-MPC is crucial, even if patients are asymptomatic.

**Introduction**

Pancreatic cancer is estimated to be the fourth leading cause of death and generally has a poor prognosis, with a 5-year overall survival (OS) rate of 10% at all stages [1]. Pancreatic cancer is difficult to diagnose at an early stage [2, 3], and more than half of patients with pancreatic cancer are diagnosed at unresectable stages [4, 5]. Chemotherapy has contributed to improvements in the prognosis of patients with unresectable pancreatic cancer [4–6].

Gemcitabine (GEM) plus nab-paclitaxel (GnP) combination chemotherapy is a standard regimen for unresectable pancreatic cancer patients with a good performance status (PS) [7]. In the phase 3 MPACT trial, GnP chemotherapy demonstrated a median OS of 8.6 months, a progression-free survival (PFS) of 4.0 months and an objective response rate (ORR) of 23% for patients with unresectable metastatic pancreatic cancer (UR-MPC) [8]. In the real world, almost all patients eventually develop the disease, and a complete cure is difficult to achieve. Selecting the appropriate patient for GnP chemotherapy is necessary. The CA19-9 [9], the serum albumin level [10], older age [10] and the neutrophil-to-lymphocyte ratio [11] have been reported as predictive and pretreatment markers of GnP chemotherapy for patients with UR-MPC. However, the association between venous thromboembolism (VTE) and the prognosis of patients receiving GnP chemotherapy has not been fully established.

Pancreatic cancer has one of the highest rates of thrombotic complications among cancers [12]. The incidence of VTE is 10–20% among all cancers [13, 14]. Thrombosis is the second leading cause of death among outpatients with cancer [13, 14]; thus, VTE is considered a potentially fatal complication in pancreatic cancer patients. Lee et al. reported that overall, VTE did not affect mortality, and the outcome of symptomatic VTE was worse than that of asymptomatic VTE [15]. By contrast, Chen et al. reported that VTE after the diagnosis of pancreatic ductal adenocarcinoma was associated with significant decreases in PFS and OS [16]. Although VTE is detected throughout the entire treatment period, the early detection of VTE predicts poor survival in UR-MPC patients who received palliative chemotherapy [17]. However, no report has evaluated the relationship between the early detection of VTE and efficacy of a specific regimen for pancreatic patients with a uniform stage. Therefore, this study aimed to clarify the impact of the early detection of VTE on the outcome of GnP chemotherapy as a first-line treatment, particularly in UR-MPC patients.

**Materials and methods**

**Study design and patients**

We retrospectively collected the clinical data of 174 patients with pathologically diagnosed unresectable metastatic pancreatic adenocarcinoma who were treated with GnP chemotherapy.
as a first-line regimen at our hospital between April 2017 and March 2020. GnP chemotherapy was administered as follows: 30 min of intravenous infusion of nab-paclitaxel at 125 mg/m² followed by 30 min of intravenous infusion of GEM at 1000 mg/m² on days 1, 8, and 15. One cycle was 28 days. The dosages and schedules of therapeutic agents were adjusted as appropriate according to the patient conditions. For each patient, the data were extracted from medical records. The following clinical parameters were obtained: age, sex, Eastern Cooperative Oncology Group (ECOG) PS, primary tumor location, biliary drainage, laboratory data (levels of white blood cells (WBCs), hemoglobin (Hb), platelets (Plt), D-dimer, and carbohydrate antigen 19–9 (CA19-9)), imaging findings before and during treatment, details of GnP chemotherapy (dosages and schedules of therapeutic agents, treatment response, and toxicities), postGnP therapeutic regimens, and OS time. Tumor responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1. Hematological and nonhematological adverse events (AEs) were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Progression-free survival (PFS) was calculated from the start date of GnP chemotherapy to the date of the assessment of progressive disease or any cause of death. OS was calculated from the start date of GnP chemotherapy to the date of death. Anemic events were defined as those requiring blood transfusion or endoscopic hemostasis. Follow-up data from patients were censored on March 31, 2021. The study was performed in accordance with the Declaration of Helsinki. Approval was obtained from the Ethics Committee of the Osaka International Cancer Center (18225–4). Informed consent was obtained using the opt-out form on the website.

**Definition of VTE**

In this study, VTE included deep venous thrombosis (DVT) of the lower extremities and pulmonary thromboembolism. VTE was diagnosed via contrast-enhanced computed tomography (CT) and/or ultrasonography. The early detection of VTE was defined as a diagnosis of VTE by the first follow-up CT scan after the initiation of chemotherapy. Patients whose VTE was detected early were classified into the VTE (+) group. Patients with symptomatic VTE were defined as those who had symptoms due to VTE at diagnosis.

**Statistical analysis**

Categorical variables were described as percentages, and continuous variables were presented as medians and ranges. The patient characteristics, treatment outcomes, and toxicities of chemotherapy were compared between the VTE (+) group and other patients (VTE (-) group) using Fisher’s exact test for categorical variables or the Mann–Whitney U test for continuous variables. The log-rank test was used to compare OS and PFS. Univariate and multivariate analyses were performed to identify significant prognostic factors associated with OS using the Cox proportional hazards model. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. Factors with P values less than 0.10 in univariate analysis were entered into multivariate Cox models. For the P value, the significance level was defined as 0.05. Statistical analyses were performed using JMP Ver. 14.0 (SAS Institute, Cary, NC, USA).

**Results**

**Patient characteristics**

The characteristics of the 174 patients included in the present study are summarized in Table 1. Seventeen patients (9.8%) were classified in the VTE (+) group, and three of them were symptomatic. Thirteen patients were diagnosed with VTE at treatment initiation. Four
patients were diagnosed after treatment initiation, and the median time to diagnosis after treatment initiation was 55 days (range: 31–71 days). The median age was similar in both groups (VTE (+), 63 years (range: 45–79 years) vs. VTE (-), 65 years (range: 41–81 years); \( P = 0.947 \)). No significant difference was found in the baseline body mass index between the two groups (VTE (+), 21.6 (range: 17.0–34.2) vs. VTE (-), 20.9 (range: 15.2–33.0); \( P = 0.187 \)). Although the proportion of male patients was lower in the VTE (+) group, the difference did not reach statistical significance (\( P = 0.073 \)). Approximately 40% of tumors in both groups were located in the pancreatic head. The percentage of patients who underwent biliary drainage was not significantly different (41.2% in the VTE (+) group vs. 31.8% in the VTE (-) group; \( P = 0.428 \)). The percentage of patients with PS = 0 was significantly lower in the VTE (+) group (35.3% in the VTE (+) group vs. 63.7% in the VTE (-) group; \( P = 0.034 \)). Although the levels of WBCs, Hb, Plt, and CA19-9 were not significantly different between the two groups, the baseline D-dimer levels were significantly higher in the VTE (+) group (\( P < 0.001 \)). In the four patients diagnosed with VTE after the start of treatment, the d-dimer levels at the time of VTE diagnosis were elevated compared with those at baseline. The median elevated D-dimer level was 2.8 mg/dl (range, 0.1–8.2 mg/dl). In the VTE (+) group, 13 patients were treated with a direct oral anticoagulant (DOAC), and 3 patients were treated with unfractionated heparin from the time of diagnosis. One patient did not receive anticoagulant therapy.

Treatment outcomes

The median follow-up period was 350 days (range, 23–1403 days). At the end of the follow-up period, 136 patients (78.1%) died or were censored. The median OS and PFS were significantly shorter in the VTE (+) group than in the VTE (-) group (OS: 259 days [95% CI: 147–312 days] vs. 400 days [95% CI: 361–478 days], \( P < 0.001 \); PFS: 120 days [95% CI: 47–155 days] vs. 162 days [95% CI: 150–86 days], \( P = 0.008 \) (Fig 1). The tumor response and dose reduction rate in the first course are summarized in Table 2. A complete response, a partial response, stable disease, and progressive disease were observed in 0, 5, 6, and 5 patients in the VTE (+) group and 1, 47, 77, and 23 patients in the VTE (-) group, respectively. The objective response rate (ORR) was 29.4% in the VTE (+) group and 30.5% in the VTE (-) group. No significant difference was found in the ORR, disease control rate or dose reduction rate in the first course between the groups.

Toxicity

No patient died because of AEs due to chemotherapy. Grade 3–4 AEs are summarized in Table 3. No significant difference was found in hematological toxicities and nonhematologic toxicities between the groups. Grade 3–4 hematologic toxicities occurred in 10 patients (58.8%) in the VTE (+) group and 102 patients (66.2%) in the VTE (-) group. Grade 3–4 nonhematologic toxicities were observed in six patients (35.3%) in the VTE (+) group and 41 patients (26.6%) in the VTE (-) group. The major grade 3–4 nonhematologic toxicities were as follows: peripheral neuropathy (5.9%/6.5%), infection (5.9%/5.2%), constipation (11.8%/3.3%), fatigue (0%/3.9%), and appetite loss (0%/3.9%). Interstitial lung disease was observed in three patients (17.6%) in the VTE (+) group and 16 patients (10.4%) in the VTE (-) group. A total of 40 anemic events occurred during the follow-up period. Although anemic events were more frequent in the VTE (+) group (six patients (35.5%)) than in the VTE (-) group (34 patients (22.1%)), the difference was not statistically significant (\( P = 0.228 \)). No deaths due to hemorrhage or anemia occurred. No cases of ischemic disease occurred during anticoagulation.
Post-GnP treatment

Post-GnP treatment is summarized in Table 4. Six patients continued GnP chemotherapy at the end of the follow-up period. One patient achieved a complete response and was under observation without treatment. Three patients underwent conversion surgery. Overall, 120 patients received second-line chemotherapy. The percentage of patients who received second-line chemotherapy was lower in the VTE (+) group than in the VTE (-) group (53.0% [9/17] versus 70.7% [111/157]; P = 0.071). The second-line therapy regimens in the VTE (+) group were modified FOLFILINOX in two patients, 5-fluorouracil (5-FU) plus nanoliposomal irinotecan (nal-IRI) in one patient, S-1 in five patients, and other regimens in one patient. In the VTE (-) group, modified FOLFILINOX was administered to 46 patients, 5-FU plus nal-IRI to eight patients, S-1 to 48 patients, pembrolizumab to one patient, an investigational agent to one patient, chemoradiation to three patients, and other regimens to four patients. The percentage of patients who chose best supportive care (BSC) was significantly higher in the VTE (+) group (47.0% [8/17] vs. 23.0% [36/157], P = 0.034).

Table 1. Patient characteristics in subgroups according to VTE (+)/VTE (-).

|                         | VTE (+)  | VTE (-) | p     |
|-------------------------|----------|---------|-------|
| Number of patients, n   | 17       | 157     |       |
| Symptomatic VTE, n (%)  | 3 (17.6%)|         |       |
| Asymptomatic VTE, n (%) | 14 (82.4%)|        |       |
| Timepoint of VTE diagnosis |         |         |       |
| At treatment initiation, n (%) | 13 (76.5%)|        |       |
| After treatment initiation, n (%) | 4 (23.5%) |    |       |
| Median time to diagnosis (range), days | 55 (31–71) |    |       |
| Median age (range), y.o. | 63 (45–79) | 65 (41–81) | 0.947† |
| Sex                      |          |         | 0.073§ |
| Male, n (%)              | 5 (29.4%)| 85 (54.1%)|       |
| Female, n (%)            | 12 (70.6%)| 72 (45.9%)|       |
| Baseline median body mass index (range) | 21.6 (17.0–34.2) | 20.9 (15.2–33.0) | 0.187† |
| Location                 |          |         | 0.958§ |
| Head, n (%)              | 7 (41.1%)| 63 (40.1%)|       |
| Body-tail, n (%)         | 10 (58.9%)| 94 (59.9%)|       |
| Performance status       |          |         | 0.034§ |
| 0                       | 6        | 100     |       |
| 1                       | 11       | 57      |       |
| Bile duct stenting: Yes, n (%) | 7 (41.2%) | 50 (31.8%) | 0.428§ |
| Median WBC (range),/μl   | 6240 (1020–14680) | 6750 (730–10970) | 0.260† |
| Median Hb (range), g/dl  | 12.7 (9.3–15.9) | 13.3 (7.8–17.2) | 0.059† |
| Median Platelet (range), 10⁴/μl | 26.9 (6.2–48.0) | 23.0 (11.7–56.5) | 0.356† |
| Median D-dimer (range), mg/dl | 3.5 (0.8–30.2) | 1.8 (0.6–16.7) | <0.001† |
| Median CA19-9 (range), mg/dl | 9000 (2–100000) | 7500 (2–100000) | 0.062† |
| Treatment for VTE        |          |         |       |
| DOAC, n (%)              | 13 (76.5%)|         |       |
| Unfractionated heparin, n (%) | 3 (17.6%) |    |       |
| None, n (%)              | 1 (5.9%) |         |       |

†, Mann–Whitney U test
§, Fisher’s exact test.
VTE, venous thromboembolism; WBC, white blood cell; Hb, hemoglobin; CA19-9, carbohydrate antigen 19–9; DOAC, direct oral anticoagulant.

https://doi.org/10.1371/journal.pone.0264653.t001

Post-GnP treatment

Post-GnP treatment is summarized in Table 4. Six patients continued GnP chemotherapy at the end of the follow-up period. One patient achieved a complete response and was under observation without treatment. Three patients underwent conversion surgery. Overall, 120 patients received second-line chemotherapy. The percentage of patients who received second-line chemotherapy was lower in the VTE (+) group than in the VTE (-) group (53.0% [9/17] versus 70.7% [111/157]; P = 0.071). The second-line therapy regimens in the VTE (+) group were modified FOLFILINOX in two patients, 5-fluorouracil (5-FU) plus nanoliposomal irinotecan (nal-IRI) in one patient, S-1 in five patients, and other regimens in one patient. In the VTE (-) group, modified FOLFILINOX was administered to 46 patients, 5-FU plus nal-IRI to eight patients, S-1 to 48 patients, pembrolizumab to one patient, an investigational agent to one patient, chemoradiation to three patients, and other regimens to four patients. The percentage of patients who chose best supportive care (BSC) was significantly higher in the VTE (+) group (47.0% [8/17] vs. 23.0% [36/157], P = 0.034).
Finally, we examined the predictive factors associated with OS (Table 5). In univariate analysis of OS, four variables were significantly associated with OS: ECOG PS (HR, 2.93; 95% CI, 2.04–4.21; \( P < 0.001 \)), VTE (+) (HR, 6.39; 95% CI, 1.40–29.0; \( P = 0.016 \)), baseline CA19-9 levels (HR, 1.62; 95% CI, 1.13–2.32; \( P = 0.008 \)) and baseline D-dimer levels (HR, 1.84; 95% CI, 1.28–2.64; \( P < 0.001 \)). Multivariate analysis was performed using these four variables. VTE was identified as a statistically significant independent predictor of OS (HR, 1.87; 95% CI, 1.02–3.44; \( P = 0.041 \)), ECOG PS (HR 2.52, 95% CI, 1.73–3.66, \( P < 0.001 \)) and the CA19-9 levels (HR 1.75, 95% CI 1.02–3.44, \( P = 0.003 \)).

**Factors associated with OS**

Finally, we examined the predictive factors associated with OS (Table 5). In univariate analysis of OS, four variables were significantly associated with OS: ECOG PS (HR, 2.93; 95% CI, 2.04–4.21; \( P < 0.001 \)), VTE (+) (HR, 6.39; 95% CI, 1.40–29.0; \( P = 0.016 \)), baseline CA19-9 levels (HR, 1.62; 95% CI, 1.13–2.32; \( P = 0.008 \)) and baseline D-dimer levels (HR, 1.84; 95% CI, 1.28–2.64; \( P < 0.001 \)). Multivariate analysis was performed using these four variables. VTE was identified as a statistically significant independent predictor of OS (HR, 1.87; 95% CI, 1.02–3.44; \( P = 0.041 \)), ECOG PS (HR 2.52, 95% CI, 1.73–3.66, \( P < 0.001 \)) and the CA19-9 levels (HR 1.75, 95% CI 1.02–3.44, \( P = 0.003 \)).

**Table 2. Tumor response and dose reduction in the 1st course of therapy.**

|                      | VTE (+) | VTE (-) | \( p \) |
|----------------------|---------|---------|---------|
| **Best Response, n** |         |         |         |
| Complete response    | 0       | 1       |         |
| Partial response     | 5       | 47      |         |
| Stable disease       | 6       | 77      |         |
| Progress disease     | 5       | 23      |         |
| Not evaluated        | 1       | 8       |         |
| **Response rate, n (%)** | 5 (29.4%) | 48 (30.5%) | 0.414 |
| **Disease control rate, n (%)** | 11 (64.7%) | 125 (79.6%) | 0.212 |
| **Dose reduction in the 1st course, n(%)** | 13 (76.4%) | 103 (65.6%) | 0.429 |

\( p \) values were calculated using Fisher’s exact test. VTE, venous thromboembolism.
This study revealed that the early detection of VTE was associated with a poor prognosis in patients with UR-MPC who underwent GnP as a first-line chemotherapy. Although VTE is considered a critical complication in patients with UR-MPC, the impact of early VTE detection remains to be fully elucidated in patients who receive multidrug combination therapy, including GnP. To our best knowledge, this report is the first to identify early VTE detection as a predictor of a poor prognosis.

### Table 3. Severe (grade 3–4) adverse events.

|                               | VTE (+) | VTE (–) | p    |
|-------------------------------|---------|---------|------|
| n = 17                        | n = 157 |         |      |
| Death due to an adverse event, n (%) | 0 (0.0%) | 0 (0.0%) |      |
| Hematologic adverse event     |         |         |      |
| (grade 3–4), n (%)            |         |         |      |
| Neutropenia                   | 4 (23.5%) | 68 (44.2%) | 0.129 |
| Leukopenia                    | 6 (35.2%) | 79 (51.3%) | 0.309 |
| Thrombocytopenia              | 2 (11.8%) | 18 (11.7%) | 1.000 |
| Anemia                        | 7 (41.2%) | 42 (27.3%) | 0.256 |
| Nonhematologic adverse event  |         |         |      |
| (occurring in >3% of patients)|         |         |      |
| Peripheral neuropathy         | 1 (5.9%) | 10 (6.5%) | 1.000 |
| Infection                     | 1 (5.9%) | 8 (5.2%) | 1.000 |
| Constipation                  | 2 (11.8%) | 5 (3.3%) | 0.141 |
| Fatigue                       | 1 (5.9%) | 6 (3.9%) | 0.519 |
| Appetite loss                 | 1 (5.9%) | 6 (3.9%) | 0.519 |
| ILD (all grade), n (%)        | 3 (17.6%) | 16 (10.4%) | 0.386 |
| Anemic events, n (%)          | 6 (35.3%) | 34 (22.1%) | 0.228 |

P values were calculated using Fisher’s exact test. ILD (all grade), and anemic events. VTE, venous thromboembolism; ILD, interstitial lung disease.

### Table 4. PostGnP treatment at the time of data cutoff.

|                               | VTE (+) | VTE (–) | p    |
|-------------------------------|---------|---------|------|
| n = 17                        | n = 157 |         |      |
| GnP-therapy ongoing, n (%)    | 0 (0.0%) | 6 (3.8%) |      |
| GnP-therapy terminated, n (%) | 17 (100.0%) | 151 (96.2%) |      |
| Complete response, n (%)      | 0 (0.0%) | 1 (0.6%) |      |
| Conversion Surgery, n (%)     | 0 (0.0%) | 3 (1.9%) |      |
| Second line chemotherapy, n (%)| 9 (53.0%) | 111 (70.7%) | 0.071 |
| mFOLFOLINOX                   | 2 (11.8%) | 46 (29.3%) |      |
| 5-FU+nal-IRI                  | 1 (5.9%) | 8 (5.1%) |      |
| S-1                           | 5 (29.4%) | 48 (30.7%) |      |
| Pembrolizumab                 | 0 (0.0%) | 1 (0.6%) |      |
| Investigational agent         | 0 (0.0%) | 1 (0.6%) |      |
| Chemoradiotherapy             | 0 (0.0%) | 3 (1.9%) |      |
| Other                         | 1 (5.9%) | 4 (2.5%) |      |
| BSC, n (%)                    | 8 (47.0%) | 36 (23.0%) | 0.034 |

P values were calculated using Fisher’s exact test. FOLFIRINOX, oxaliplatin, irinotecan, 5-FU and leucovorin; nal-IRI, nanoliposomal irinotecan; BSC, best supportive care.

**Discussion**

This study revealed that the early detection of VTE was associated with a poor prognosis in patients with UR-MPC who underwent GnP as a first-line chemotherapy. Although VTE is considered a critical complication in patients with UR-MPC, the impact of early VTE detection remains to be fully elucidated in patients who receive multidrug combination therapy, including GnP. To our best knowledge, this report is the first to identify early VTE detection as a predictor of a poor prognosis.
as a prognostic factor for patients with UR-MPC who receive first-line GnP chemotherapy, which is a standard chemotherapeutic regimen. Based on the results described above, we uncovered the following three crucial findings.

First, the OS and PFS were significantly shorter in the VTE (+) group in this study. The OS and PFS of the VTE (-) and VTE (+) groups were 400 vs. 259 days (OS; \( P < 0.001 \)) and 162 vs. 120 days (PFS; \( P = 0.008 \)), respectively. In a Japanese phase 1/2 study, GnP chemotherapy led to median PFS and OS times of 6.5 months (95% CI, 5.1–8.3) and 13.5 months (95% CI, 10.6—not reached), respectively [18]. Our results showed that the OS and PFS in the VTE (-) group were similar to those in the Japanese phase 1/2 study, and the OS and PFS were both significantly shorter in the VTE (+) group than in the VTE (-) group. Although previous retrospective studies reported no association between VTE and overall survival (OS) in pancreatic cancer patients [19, 20], recent studies have reported that the diagnosis of VTE was associated with a 1.6-fold risk decrease in OS [21]. This difference was presumably due to the improved OS associated with the progression in chemotherapy and supportive care. Additionally, our results revealed more patients with advanced disease in the VTE (+) group. In the VTE (+) group, a high proportion of patients had higher CA19-9 levels and a low percentage of patients had PS = 0. Although the RR, disease control rate and dose reduction in the first course were not significantly different in VTE (+) and VTE (-) groups, the proportion of patients who chose BSC after GnP chemotherapy was significantly higher in the VTE (+) group. Patients in the VTE (+) group likely could not receive second-line chemotherapy because of the worsening of their general condition at the time of disease progression. Our analysis implies that the early diagnosis of VTE is associated with potential pancreatic cancer progression and reduces the probability of post-GnP treatment.

Second, more than 80% of the patients in the VTE (+) group were asymptomatic. In our study, all asymptomatic patients with high D-dimer levels underwent ultrasonography of the lower extremities to exclude DVT, enabling us to detect asymptomatic cases. A systematic review of patients with pancreatic carcinoma reported that the incidence of VTE was 5.0–36.0% [22]. In a Japanese cohort of 107 chemo-naïve patients with pancreatic cancer, 17 (16.5%) were diagnosed with VTE; in particular, only 3 patients were symptomatic [23]. Although VTE is a potentially fatal disease, pancreatic cancer patients with VTE rarely have

| Table 5. Univariate and multivariate analyses of OS. |
|---------------------------------------------------|
| **Univariate analysis** | **Multivariate analysis** |
| **HR** | **95% CI** | **p** | **HR** | **95% CI** | **p** |
| Age (>70 vs. <70, y.o.) | 1.19 | 0.79–1.80 | 0.389 | | |
| Male vs. Female | 0.85 | 0.47–1.52 | 0.594 | | |
| Performance status (1 vs. 0) | 2.93 | 2.04–4.21 | <0.001 | 2.52 | 1.73–3.66 | <0.001 |
| Tumor location (Head vs. other) | 1.17 | 0.38–1.67 | 0.388 | | |
| VTE (VTE(+) vs. VTE(-)) | 6.39 | 1.40–29.0 | 0.016 | 1.87 | 1.02–3.44 | 0.041 |
| Bile duct stenting (Y vs. N) | 1.16 | 0.80–1.68 | 0.409 | | |
| Baseline WBC (>9000 vs. ≤9000, μL) | 1.92 | 0.81–4.59 | 0.136 | | |
| Baseline Hb (<10.0 vs. ≥10.0, g/dL) | 1.38 | 0.60–3.14 | 0.442 | | |
| Baseline Platelet (>25.0 vs. ≤25.0, ×10^4/μL) | 1.04 | 0.72–1.50 | 0.802 | | |
| Baseline CA19-9 (>1000 vs. ≤1000, U/mL) | 1.62 | 1.13–2.32 | 0.008 | 1.75 | 1.02–3.44 | 0.003 |
| Baseline D-dimer (>2.0 vs.≤2.0, μg/mL) | 1.84 | 1.28–2.64 | <0.001 | 1.48 | 0.99–2.20 | 0.051 |

Univariate and multivariate analyses of these variables were performed using the Cox proportional hazard regression model. OS, overall survival; WBC, white blood cell; Hb, hemoglobin

https://doi.org/10.1371/journal.pone.0264653.t005
comorbid symptoms of VTE. In our study, the total incidence rate of VTE (9.7%) was not higher than that in previous reports because of the limited period of diagnosis. Additionally, the high proportion of asymptomatic cases (> 80%) was similar to that of a previously described Japanese cohort [23]. Asymptomatic patients likely could not be diagnosed with VTE because of the measurement of the D-dimer level at diagnosis and follow-up. Asymptomatic VTE is difficult to detect without various assessments. Therefore, not only diagnostic imaging tests, such as CT scans but also useful biomarker assessments are needed to detect asymptomatic VTE. Patients with VTE frequently exhibited elevated D-dimer, fibrin degradation product, and IL-6 levels. Additionally, factor VIII, D-dimers, von Willebrand factor, free tissue factor pathway inhibitors, microvesicle-tissue factor activity and CA 19–9 levels have been reported as important biomarkers to assess VTE risk [24]. Among these biomarkers, D-dimer is particularly useful because of the correlation among pancreatic cancer, coagulation activity and fibrinolysis [23]. Thus, our study showed that monitoring the D-dimer levels at and after treatment initiation may be a highly sensitive method for the early diagnosis of asymptomatic VTE. The early diagnosis of VTE can contribute to the prevention of fatal VTE, as described below. Additionally, although more than 80% of patients were asymptomatic, early VTE detection was a poor prognostic factor for GnP chemotherapy as the first-line regimen.

Third, our results showed that no patient had recurrent VTE or ischemic disease, including brain infarction and myocardial infarction, during anticoagulation, and no difference was found in the frequency of severe anemia events between the groups. Almost all the patients in the VTE (+) group were treated with a direct oral anticoagulant (DOAC) or unfractionated heparin from the time of diagnosis, and all the patients continued to receive thromboprophylaxis unless they had a severe anemia event. Anticoagulation therapy has been recommended to prevent the worsening of VTE and reduce mortality. By contrast, VTE has a high recurrence rate, and anticoagulation is associated with bleeding events, including gastrointestinal bleeding [14, 25]. Recently, a meta-analysis of 1003 pancreatic cancer patients has revealed that anticoagulation therapy significantly reduced the risk of symptomatic VTE without increasing major bleeding [26]. Considering these results, the International Initiative on Thrombosis and Cancer (14) and American Society of Clinical Oncology Clinical Practice [25] guidelines recommend anticoagulation therapy with apixaban or rivaroxaban in cancer outpatients undergoing chemotherapy with a Khorana score ≥ 2, no bleeding risk and no drug-drug interactions (Grade 1B) [14]. Thus, these guidelines indicate that thromboprophylaxis may now be considered in all ambulatory pancreatic cancer patients, given that 2 points are assigned for the primary site being the pancreas in the Khorana score [27]. However, the benefit of anticoagulation therapy in these patients continues to be underrecognized worldwide. The reasons for this are mainly due to the fear of severe bleeding and inherent costs for anticoagulant therapy [28]. Given the short OS of pancreatic cancer mentioned above, no strong evidence exists that anticoagulation therapy has contributed to improving the overall survival of advanced pancreatic cancer patients who receive chemotherapy [16, 29, 30]. Based on these data, anticoagulation therapy effectively prevented ischemic diseases. Taken together, we suggest that the indications and durations for anticoagulation therapy must be adjusted in each patient, and appropriate follow-up evaluations are also required to detect severe anemia due to gastrointestinal bleeding and/or myelosuppression.

This study has limitations. First, this study was a single-center, retrospective analysis. Treatment evaluation was based on the judgment of each attending physician, and secondary evaluations were not performed in this study. Second, the sample size of the study was small. Thus, to clarify the significance of the early detection of VTE, further multicenter, large-scale and prospective studies are required.
In conclusion, early detection of VTE predicts a poor prognosis in patients with UR-MPC who receive first-line GnP chemotherapy. Our investigation indicates that screening for VTE in patients with UR-MPC will be crucial, even if the patients are asymptomatic.

Author Contributions
Conceptualization: Takuo Yamai.
Data curation: Erika Hiraga, Yasuharu Kawamoto, Takeru Hirao, Kazuma Daiku, Shingo Maeda.
Investigation: Nobuyasu Fukutake.
Supervision: Masashi Fujita, Kazuyoshi Ohkawa.
Writing – original draft: Takuo Yamai.
Writing – review & editing: Kenji Ikezawa, Yasuharu Kawamoto, Takeru Hirao, Sena Higashii, Kazuma Daiku, Shingo Maeda, Yutaro Abe, Makiko Urabe, Yugo Kai, Ryoji Takada, Tasuku Nakabori, Hiroyuki Uehara.

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7–33. https://doi.org/10.3322/caac.21654 PMID: 33433946
2. Gheorghe G, Bungau S, Ilie M, Behl T, Vesa CM, Brisc C, et al. Early Diagnosis of Pancreatic Cancer: The Key for Survival. Diagnostics (Basel). 2020; 10(11). https://doi.org/10.3390/diagnostics10110869 PMID: 33114412
3. Fukuda J, Ikezawa K, Nakao M, Okagaki S, Ashida R, Ioka T, et al. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Cancers (Basel). 2021; 13(3). https://doi.org/10.3390/cancers13030502 PMID: 33525645
4. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018; 18(1):688. https://doi.org/10.1186/s12885-018-4610-4 PMID: 29940910
5. Tempero MA, Malafa MP, Al-Hawary M, Behrman AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(4):439–57. https://doi.org/10.6004/jnccn.2021.0017 PMID: 33845462
6. Ikezawa K, Kyotani R, Takada R, Daiku K, Maeda S, Imai T, et al. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. JGH Open. 2021; 5(6):679–85. https://doi.org/10.1002/jgh3.12555 PMID: 34124386
7. Okusaka T, Furuse J. Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines. J Gastroenterol. 2020; 55(4):369–82. https://doi.org/10.1007/s00535-020-01666-y PMID: 31997007
8. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691–703. https://doi.org/10.1056/NEJMoa1304369 PMID: 24131140
9. Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015; 107(2). https://doi.org/10.1093/jnci/dju413 PMID: 25638248
10. Blomstrand H, Green H, Fredrikson M, Gränmark E, Björnsson B, Elander NO. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer. 2020; 20(1):950. https://doi.org/10.1186/s12885-020-07426-8 PMID: 33008332
11. Chen Y, Liao Y, Lam LM, He L, Tsang YS, Di YS, et al. Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio. Int J Med Sci. 2020; 17(10):1449–57. https://doi.org/10.7150/ijms.46254 PMID: 32624701
12. Blom JW, Vanderschoot JP, Oostindíder MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J
Thromb Haemost. 2006; 4(3):529–35. https://doi.org/10.1111/j.1538-7836.2006.01804.x PMID: 16460435

13. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119(3):648–55. https://doi.org/10.1002/cncr.27772 PMID: 22893596

14. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019; 20(10):e566–e81. https://doi.org/10.1016/S1470-2045(19)30336-5 PMID: 31492632

15. Jong-Chan Lee YR, Junhyeon Cho, et al. Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnicities: A Large Population-Based Observational Study. Medicine: Wolters Kluwer Health, Inc.; 2016. p. e3472.

16. Frere C, Bourem B, Gourgou S, Fraisse J, Canivet C, Connors JM, et al. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Gastroenterology. 2020; 158(5):1346–58.e4. https://doi.org/10.1053/j.gastro.2019.12.009 PMID: 31843588

17. Chen JS, Hung CY, Chang H, Liu CT, Chen YY, Lu CH, et al. Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers (Basel). 2018; 10(12). https://doi.org/10.3390/cancers10120501 PMID: 30544670

18. Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016; 77(3):595–603. https://doi.org/10.1007/s00280-016-2972-3 PMID: 26842789

19. Shaib W, Deng Y, Zilterman D, Lundberg B, Saif MW. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res. 2010; 30(10):4261–4. PMID: 21036750

20. Lee JC, Ro YS, Cho J, Park Y, Lee JH, Hwang JH, et al. Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnicities: A Large Population-Based Observational Study. Medicine (Baltimore). 2016; 95(17):e3472. https://doi.org/10.1097/MD.00000000000003472 PMID: 27124043

21. Mandalà M, Reni M, Cascini S, Barni S, Floriani I, Cereda S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007; 18(10):1660–5. https://doi.org/10.1093/annonc/mdm284 PMID: 17660490

22. Epstein AS, O’Reilly EM. Exocrine pancreas cancer and thromboembolic events: a systematic literature review. J Natl Compr Canc Netw. 2012; 10(7):835–46. https://doi.org/10.6004/jnccn.2012.0087 PMID: 22773799

23. Kondo S, Sasaki M, Hosoi H, Sakamoto Y, Morizane C, Ueno H, et al. Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. Oncotarget. 2018; 9(24):16883–90. https://doi.org/10.18632/oncotarget.24721 PMID: 29682191

24. Faille D, Bourienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget. 2018; 9(41):26453–65. https://doi.org/10.18632/oncotarget.25458 PMID: 29899870

25. Key NS, Khorana AA, Kuderer NM, Bohike K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020; 38(5):496–520. https://doi.org/10.1200/JCO.19.01461 PMID: 31381464

26. Frere C, Cricchi B, Bourem B, Canivet C, Abdallah NA, Buscall L, et al. Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2020; 12(8). https://doi.org/10.3390/cancers12082028 PMID: 3272064

27. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902–7. https://doi.org/10.1182/blood-2007-10-116327 PMID: 18216292

28. Frere C. Burden of venous thromboembolism in patients with pancreatic cancer. World J Gastroenterol. 2021; 27(19):3235–40. https://doi.org/10.3748/wjg.v27.i19.3235 PMID: 34040325

29. Maraveyas A, Watkins J, Roy R, Fyle D, Propper D, Loffs F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012; 48(9):1263–92. https://doi.org/10.1161/ejca.2011.01017 PMID: 22109080

30. Pelzer U, Opitz B, Deutschendorf G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. J Clin Oncol. 2015; 33(18):2028–34. https://doi.org/10.1200/JCO.2014.55.1481 PMID: 25987694